A30 BIOMARKERS IN THORACIC ONCOLOGY: PREDICTING OUTCOMES: Mass Spectrometry Based Proteomic Analysis For Prognostication In Lung Cancer

A30 BIOMARKERS IN THORACIC ONCOLOGY: PREDICTING OUTCOMES: Mass Spectrometry Based Proteomic Analysis For Prognostication In Lung Cancer

Despite multibillion dollar research in discovery of newer treatment options, the overall five-year survival rate remains very poor. [...]there is a need for predictive tests that can identify which therapies are most appropriate for individual patients and assess their outcome. [...]prevalence of E...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser: Ratcliff, S, Ifeacho, V, Santiago, T, Upadhyay, D, Peterson, M
Format: Artikel
Sprache:eng
Schlagworte:
Lung cancer
Mass spectrometry
Medical prognosis
Mutation
Patients
Scientific imaging
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Despite multibillion dollar research in discovery of newer treatment options, the overall five-year survival rate remains very poor. [...]there is a need for predictive tests that can identify which therapies are most appropriate for individual patients and assess their outcome. [...]prevalence of EGFR mutation is
ISSN:1073-449X
1535-4970